Alaunos Therapeutics, Inc.
TCRTNASDAQHealthcare● Active
$2.00
$-0.28(-12.28%)
Market Cap$4884292
P/E Ratio—
52W High$6.2
52W Low$1.67
Alaunos Therapeutics, Inc. (TCRT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
TCRT · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.59
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
🔥 8-Quarter EPS Beat Streak
TCRT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 18, 2026 | — | — | — | — | — | — |
| — Q2 FY2026 | May 15, 2026 | — | -$0.59 | — | — | — | — |
| ▲ Q1 FY2026 | Mar 31, 2026 | -$3.69 | -$0.40 | +89.2% | $0.00B | $0.00B | +0.0% |
| ▲ Q4 FY2025 | Nov 14, 2025 | -$4.90 | -$0.55 | +88.8% | — | — | — |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$5.33 | -$0.63 | +88.2% | — | — | — |
| ▲ Q2 FY2025 | May 15, 2025 | -$6.44 | -$0.67 | +89.6% | $0.00B | — | — |
| ▲ Q1 FY2025 | Mar 31, 2025 | -$4.50 | -$0.46 | +89.8% | $0.00B | — | — |
| ▲ Q4 FY2024 | Nov 14, 2024 | -$4.50 | -$0.70 | +84.4% | — | — | — |
Q3 FY2026
Aug 18, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026
EPS Actual
-$0.59
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 31, 2026Beat
EPS Actual
-$0.40
EPS Est.
-$3.69
EPS Surpr.
+89.2%
Revenue
$0.00B
Q4 FY2025
Nov 14, 2025Beat
EPS Actual
-$0.55
EPS Est.
-$4.90
EPS Surpr.
+88.8%
Revenue
—
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$0.63
EPS Est.
-$5.33
EPS Surpr.
+88.2%
Revenue
—
Q2 FY2025
May 15, 2025Beat
EPS Actual
-$0.67
EPS Est.
-$6.44
EPS Surpr.
+89.6%
Revenue
$0.00B
Q1 FY2025
Mar 31, 2025Beat
EPS Actual
-$0.46
EPS Est.
-$4.50
EPS Surpr.
+89.8%
Revenue
$0.00B
Q4 FY2024
Nov 14, 2024Beat
EPS Actual
-$0.70
EPS Est.
-$4.50
EPS Surpr.
+84.4%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $-3.69 | $-3.69 | $-3.69 | 1 |
| Q3 FY2025 | $-4.90 | $-4.90 | $-4.90 | 1 |
| Q3 FY2019 | $-13.50 | $-13.50 | $-13.50 | 1 |
| Q2 FY2019 | $-12.75 | $-12.75 | $-12.75 | 1 |
| Q1 FY2019 | $-12.50 | $-12.50 | $-12.50 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2019 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2019 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2019 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2026 | May 15, 2026 | — | $2.52 | $2.47 | -1.98% |
| ▲ Q1 FY2026 | Mar 31, 2026 | +89.2% | $2.82 | $2.86 | +1.42% |
| ▲ Q4 FY2025 | Nov 14, 2025 | +88.8% | $2.85 | $2.97 | +4.21% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +88.2% | $2.39 | $2.40 | +0.42% |
| ▲ Q2 FY2025 | May 15, 2025 | +89.6% | $2.89 | $2.82 | -2.42% |
| ▲ Q1 FY2025 | Mar 31, 2025 | +89.8% | $1.46 | $1.47 | +0.68% |
| ▲ Q4 FY2024 | Nov 14, 2024 | +84.4% | $2.40 | $2.34 | -2.50% |
| ▲ Q3 FY2024 | Aug 14, 2024 | +84.2% | $2.50 | $2.42 | -3.20% |
Q2 FY2026-1.98%
Report Date
May 15, 2026
EPS Beat/Miss
—
Price Before
$2.52
Price After
$2.47
Q1 FY2026+1.42%
Report Date
Mar 31, 2026
EPS Beat/Miss
+89.2%
Price Before
$2.82
Price After
$2.86
Q4 FY2025+4.21%
Report Date
Nov 14, 2025
EPS Beat/Miss
+88.8%
Price Before
$2.85
Price After
$2.97
Q3 FY2025+0.42%
Report Date
Aug 14, 2025
EPS Beat/Miss
+88.2%
Price Before
$2.39
Price After
$2.40
Q2 FY2025-2.42%
Report Date
May 15, 2025
EPS Beat/Miss
+89.6%
Price Before
$2.89
Price After
$2.82
Q1 FY2025+0.68%
Report Date
Mar 31, 2025
EPS Beat/Miss
+89.8%
Price Before
$1.46
Price After
$1.47
Q4 FY2024-2.50%
Report Date
Nov 14, 2024
EPS Beat/Miss
+84.4%
Price Before
$2.40
Price After
$2.34
Q3 FY2024-3.20%
Report Date
Aug 14, 2024
EPS Beat/Miss
+84.2%
Price Before
$2.50
Price After
$2.42
Avg Beat Reaction-0.20%
Beat Rate7 / 8 quarters
Largest Move+4.21% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: TCRT ends December
Alaunos Therapeutics, Inc. (TCRT) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.59 (in line with the analyst consensus of —). TCRT has beaten EPS estimates for 8 consecutive quarters. The next TCRT earnings date is expected around September 1, 2026.
Each quarter, investors track TCRT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. TCRT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
TCRT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
TCRT earnings · 4 questionsAlaunos Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. TCRT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; TCRT historically reports after market close (AMC).
TCRT earnings datewhen is TCRT earningsTCRT next earnings datewhen does TCRT report earningsTCRT earnings calendar
▸ Source: FMP · Alaunos Therapeutics, Inc. SEC filings · US GAAP · Alaunos Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026